Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[NukeJohn]

The studies will continue to prove Anatabine is one of the most significant medical discoveries of the decade. More and more of these studies will be published as researchers test anatabine citrate for numerous CNS afflictions and chronic inflammation related diseases (including many auto-immune diseases).

Roskamp Institute Scientists will be attending and presenting at the National Neurotrauma Society's 2014 Neurotrauma Symposium June 29 - July 02.

https://www.facebook.com/TheRoskampInstitute

Roskamp will make three presentations at the Symposium. One of the presentations is (Spatial Memory Normalization after treatment with Anatabine Beginning 9 Months after Repetitive Mild TBI)

I search for the abstract on the conference website after you made this post. Here is the link...

https://schmitzmine.eu/omnis/OmnisWeb.acgi?Process=AHS_ShowAbstarct&Meeting=NNS2014&AbstractID=269&Action=Show&;



Internet Submitted Abstract Form No. 10269
Abstract view:
D1-23
SPATIAL MEMORY NORMALIZATION AFTER TREATMENT WITH ANATABINE BEGINNING 9 MONTHS AFTER REPETITIVE MILD TBI
Ferguson, S.A.1, 2, Mouzon, B.1, 2, Abdullah, L.1, Crynen, G.1, Mathura, V.1, Mullan, M.1, 2, Crawford, F.1, 2
1 Roskamp Institute, Sarasota, USA
2 James A. Haley Veteran's Hospital, Tampa, USA

TBI is a serious illness with long term consequences, even after mild injuries, which involve chronic neuro­in­flam­matory and neuro­degenerative pathways. Pre­viously we reported on the po­tential of anatabine to affect neuro­in­flam­mation and impro­ve memory when taken acutely after TBI. We have continued to char­acter­ize anatabine’s effects in a crossover study as a continuation of our pre­vious work.

We pre­viously pre­sented sig­nifi­cant impro­vements in spatial memory and patho­logical outcome after treat­ment with anatabine beginning acutely after repetitive mild TBI (r-mTBI). In the pre­vious study, we treated mice orally with anatabine, administered in their water through­out the study starting 30 minutes after r-mTBI or r-sham. Untreated mice (both r-sham and r-mTBI) received regular water. Although we did not see a sig­nifi­cant impro­vement to the neuro­be­havioral outcomes at acute timepoin­ts, at a chronic timepoin­t 6 months after injury we saw a sig­nifi­cant impro­vement of spatial memory of the anatabine treated r-mTBI mice com­pared to untreated r-mTBI mice, with anatabine treated r-mTBI mice performing as well as r-sham mice. At 9 months, 4 mice per group were euthanized, revealing regionally-spe­ci­fic re­ductions in IBA1 and GFAP staining in the anatabine treated r-mTBI mice.

We have continued to char­acter­ize the surviving mice using a crossover study. Both r-mTBI and r-sham mice that were pre­viously untreated were given anatabine starting at the 9 month timepoin­t. Mice that pre­viously received anatabine began receiving regular water only. The mice were re-evalu­ated using the Barnes maze at 12 and 18 months post-injury. Although r-mTBI mice that began taking anatabine at 9 months post-TBI initially continued to perform worse than shams at the 12 month timepoin­t, by 18 months there were no sig­nifi­cant differences in spatial memory be­tween any group. Anatabine shows po­tential at impro­ving memory fol­lowing TBI, mitigating against patho­genic neuro­in­flam­mation, and may have a long thera­peutic window.

Keywords: TBI, Neuroprotection, Neuroinflammation